Pharmaceutical Asset Management - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB509246408

Publication Date:

September 10, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Pharmaceutical Asset Management was estimated to be worth US$ 109 million in 2023 and is forecast to a readjusted size of US$ 149.7 million by 2030 with a CAGR of 4.7% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical Asset Management, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pharmaceutical Asset Management by region & country, by Type, and by Application.
The Pharmaceutical Asset Management market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical Asset Management.
麻豆原创 Segmentation
By Company
McKesson Corporation
Cerner Corporation
Siemens Healthcare
GE Healthcare
Allscripts
Epic System
IBM Corporation
Segment by Type:
Hardware(Pharma Asset)
Software(Pharma Asset)
Segment by Application
Anti-drug Counterfeiting
Supply Chain Management
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pharmaceutical Asset Management manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pharmaceutical Asset Management in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pharmaceutical Asset Management in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Pharmaceutical Asset Management Product Introduction
1.2 Global Pharmaceutical Asset Management 麻豆原创 Size Forecast
1.3 Pharmaceutical Asset Management 麻豆原创 Trends & Drivers
1.3.1 Pharmaceutical Asset Management Industry Trends
1.3.2 Pharmaceutical Asset Management 麻豆原创 Drivers & Opportunity
1.3.3 Pharmaceutical Asset Management 麻豆原创 Challenges
1.3.4 Pharmaceutical Asset Management 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Pharmaceutical Asset Management Players Revenue Ranking (2023)
2.2 Global Pharmaceutical Asset Management Revenue by Company (2019-2024)
2.3 Key Companies Pharmaceutical Asset Management Manufacturing Base Distribution and Headquarters
2.4 Key Companies Pharmaceutical Asset Management Product Offered
2.5 Key Companies Time to Begin Mass Production of Pharmaceutical Asset Management
2.6 Pharmaceutical Asset Management 麻豆原创 Competitive Analysis
2.6.1 Pharmaceutical Asset Management 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Pharmaceutical Asset Management Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical Asset Management as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Hardware(Pharma Asset)
3.1.2 Software(Pharma Asset)
3.2 Global Pharmaceutical Asset Management Sales Value by Type
3.2.1 Global Pharmaceutical Asset Management Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Pharmaceutical Asset Management Sales Value, by Type (2019-2030)
3.2.3 Global Pharmaceutical Asset Management Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Anti-drug Counterfeiting
4.1.2 Supply Chain Management
4.2 Global Pharmaceutical Asset Management Sales Value by Application
4.2.1 Global Pharmaceutical Asset Management Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Pharmaceutical Asset Management Sales Value, by Application (2019-2030)
4.2.3 Global Pharmaceutical Asset Management Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Pharmaceutical Asset Management Sales Value by Region
5.1.1 Global Pharmaceutical Asset Management Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Pharmaceutical Asset Management Sales Value by Region (2019-2024)
5.1.3 Global Pharmaceutical Asset Management Sales Value by Region (2025-2030)
5.1.4 Global Pharmaceutical Asset Management Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Pharmaceutical Asset Management Sales Value, 2019-2030
5.2.2 North America Pharmaceutical Asset Management Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Pharmaceutical Asset Management Sales Value, 2019-2030
5.3.2 Europe Pharmaceutical Asset Management Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Pharmaceutical Asset Management Sales Value, 2019-2030
5.4.2 Asia Pacific Pharmaceutical Asset Management Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Pharmaceutical Asset Management Sales Value, 2019-2030
5.5.2 South America Pharmaceutical Asset Management Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Pharmaceutical Asset Management Sales Value, 2019-2030
5.6.2 Middle East & Africa Pharmaceutical Asset Management Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Pharmaceutical Asset Management Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Pharmaceutical Asset Management Sales Value
6.3 United States
6.3.1 United States Pharmaceutical Asset Management Sales Value, 2019-2030
6.3.2 United States Pharmaceutical Asset Management Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Pharmaceutical Asset Management Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Pharmaceutical Asset Management Sales Value, 2019-2030
6.4.2 Europe Pharmaceutical Asset Management Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Pharmaceutical Asset Management Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Pharmaceutical Asset Management Sales Value, 2019-2030
6.5.2 China Pharmaceutical Asset Management Sales Value by Type (%), 2023 VS 2030
6.5.3 China Pharmaceutical Asset Management Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Pharmaceutical Asset Management Sales Value, 2019-2030
6.6.2 Japan Pharmaceutical Asset Management Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Pharmaceutical Asset Management Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Pharmaceutical Asset Management Sales Value, 2019-2030
6.7.2 South Korea Pharmaceutical Asset Management Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Pharmaceutical Asset Management Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Pharmaceutical Asset Management Sales Value, 2019-2030
6.8.2 Southeast Asia Pharmaceutical Asset Management Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Pharmaceutical Asset Management Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Pharmaceutical Asset Management Sales Value, 2019-2030
6.9.2 India Pharmaceutical Asset Management Sales Value by Type (%), 2023 VS 2030
6.9.3 India Pharmaceutical Asset Management Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 McKesson Corporation
7.1.1 McKesson Corporation Profile
7.1.2 McKesson Corporation Main Business
7.1.3 McKesson Corporation Pharmaceutical Asset Management Products, Services and Solutions
7.1.4 McKesson Corporation Pharmaceutical Asset Management Revenue (US$ Million) & (2019-2024)
7.1.5 McKesson Corporation Recent Developments
7.2 Cerner Corporation
7.2.1 Cerner Corporation Profile
7.2.2 Cerner Corporation Main Business
7.2.3 Cerner Corporation Pharmaceutical Asset Management Products, Services and Solutions
7.2.4 Cerner Corporation Pharmaceutical Asset Management Revenue (US$ Million) & (2019-2024)
7.2.5 Cerner Corporation Recent Developments
7.3 Siemens Healthcare
7.3.1 Siemens Healthcare Profile
7.3.2 Siemens Healthcare Main Business
7.3.3 Siemens Healthcare Pharmaceutical Asset Management Products, Services and Solutions
7.3.4 Siemens Healthcare Pharmaceutical Asset Management Revenue (US$ Million) & (2019-2024)
7.3.5 GE Healthcare Recent Developments
7.4 GE Healthcare
7.4.1 GE Healthcare Profile
7.4.2 GE Healthcare Main Business
7.4.3 GE Healthcare Pharmaceutical Asset Management Products, Services and Solutions
7.4.4 GE Healthcare Pharmaceutical Asset Management Revenue (US$ Million) & (2019-2024)
7.4.5 GE Healthcare Recent Developments
7.5 Allscripts
7.5.1 Allscripts Profile
7.5.2 Allscripts Main Business
7.5.3 Allscripts Pharmaceutical Asset Management Products, Services and Solutions
7.5.4 Allscripts Pharmaceutical Asset Management Revenue (US$ Million) & (2019-2024)
7.5.5 Allscripts Recent Developments
7.6 Epic System
7.6.1 Epic System Profile
7.6.2 Epic System Main Business
7.6.3 Epic System Pharmaceutical Asset Management Products, Services and Solutions
7.6.4 Epic System Pharmaceutical Asset Management Revenue (US$ Million) & (2019-2024)
7.6.5 Epic System Recent Developments
7.7 IBM Corporation
7.7.1 IBM Corporation Profile
7.7.2 IBM Corporation Main Business
7.7.3 IBM Corporation Pharmaceutical Asset Management Products, Services and Solutions
7.7.4 IBM Corporation Pharmaceutical Asset Management Revenue (US$ Million) & (2019-2024)
7.7.5 IBM Corporation Recent Developments
8 Industry Chain Analysis
8.1 Pharmaceutical Asset Management Industrial Chain
8.2 Pharmaceutical Asset Management Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Pharmaceutical Asset Management Sales Model
8.5.2 Sales Channel
8.5.3 Pharmaceutical Asset Management Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

McKesson Corporation
Cerner Corporation
Siemens Healthcare
GE Healthcare
Allscripts
Epic System
IBM Corporation

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.